Keyphrases
Tolerability
100%
Interleukin-17 (IL-17)
100%
Psoriatic Arthritis
100%
Interleukin-23 (IL-23)
100%
Comparative Effectiveness
100%
Target Trial Emulation
100%
TNF Inhibitors
71%
Drug Survival
42%
Clinical Outcomes
28%
Hazard Ratio
28%
Treatment Outcome
14%
Prospective Cohort Study
14%
Response Rate
14%
Adjusted Model
14%
Treatment Assignment
14%
Clinical Examination
14%
Group Level
14%
Survival Rate
14%
Survival Outcomes
14%
Target Trial
14%
Response Change
14%
Proportional Hazards Model
14%
Observational Data
14%
Individualized Treatment
14%
Biologic DMARDs
14%
Survival Treatment
14%
Propensity Score Adjustment
14%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor
100%
Tolerability
100%
Tumor Necrosis Factor Inhibitor
100%
Psoriatic Arthritis
100%
Interleukin 17
100%
Prospective Cohort Study
20%
Survival Rate
20%